Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Here’s Why

Pharvaris N.V. (NASDAQ:PHVS) shares hit a new 52-week high on Thursday . The stock traded as high as $30.24 and last traded at $30.04, with a volume of 239282 shares traded. The stock had previously closed at $29.15.

Wall Street Analyst Weigh In

PHVS has been the topic of several research reports. Royal Bank Of Canada reduced their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.73.

Pharvaris Stock Up 3.1%

The firm’s 50 day simple moving average is $27.37 and its 200 day simple moving average is $25.79. The company has a market capitalization of $1.96 billion, a PE ratio of -8.91 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, sell-side analysts predict that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Insider Buying and Selling

In other Pharvaris news, CEO Berndt Modig sold 23,333 shares of Pharvaris stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the transaction, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at $3,941,410.16. The trade was a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 11.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. General Atlantic L.P. boosted its stake in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC boosted its stake in Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after buying an additional 368,000 shares during the period. venBio Partners LLC boosted its stake in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after buying an additional 350,000 shares during the period. Deerfield Management Company L.P. boosted its stake in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after buying an additional 425,000 shares during the period. Finally, Commodore Capital LP boosted its stake in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.